PDCD1 and hepatocellular carcinoma: In conclusion, baseline LS values of tumorous foci by SWE prior to initiation of treatment with a PD-1 inhibitor plus lenvatinib were found to conveniently predict PD-1 inhibitor efficacy in patients with advanced HCC.